Japan's Clinical Trial Costs Average ¥2 Million; Number Of Trials On The Rise
This article was originally published in PharmAsia News
TOKYO - The number of clinical trials being performed in Japan is trending upward every year, but trial costs fluctuate sharply from year to year, according to survey results released by Japan's Pharmaceutical Manufacturers Association
You may also be interested in...
Japan's drug review body, the Pharmaceutical and Medical Device Agency, has significantly improved performance of the drug review process, demonstrated by shortened review times and higher satisfaction ratings, said the Office of Pharmaceutical Industry Research, a policy think tank under the industry trade association Japan Pharmaceutical Manufacturers Association
Japan's Pharmaceuticals and Medical Devices Agency has kicked off a five-year program aimed at reducing the time it takes to get a drug to market. The plan also is intended to step up the country's participation in worldwide clinical trials, an increasing trend in the pharmaceutical industry. PMDA also has a pilot program consisting of a scientific consultation for companies to use before they submit applications for approval of new drugs. The pre-review consultation is designed to occur during Phase III trials. (Click here for more
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).